• 1
    Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51: 15461554.
  • 2
    Francis PT, Holmes C, Webster MT, Stratmann GC, Procter AW, Bowen DM. Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. Dementia 1993; 4: 172179.
  • 3
    Proctor AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10: 8084.
  • 4
    Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: Treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58: 212216.
  • 5
    Ikeda M, Shigenobu K, Fukuhara R et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frototemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004; 17: 117121.
  • 6
    Iwasaki K, Satoh-Nakagawa T, Maruyama M et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005; 66: 248252.
  • 7
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 23082314.
  • 8
    Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996; 9: 16.
  • 9
    Shigenobu K, Ikeda M, Fukuhara R et al. Reducing the burden of care for Alzheimer's disease through the amelioration of ‘delusions of theft’ by drug therapy. Int J Geriatr Psychiatry 2002; 17: 211217.
  • 10
    Shigenobu K, Ikeda M, Fukuhara R et al. The Stereotypy Rating Inventory for frontotemporal lobar degeneration. Psychiatry Res 2002; 11: 175187.
  • 11
    Miyaoka T, Furuya M, Yasuda H, Hayashia M, Inagaki T, Horiguchi J. Yi-gan san for the treatment of boderline personality disoreder: An openlabel study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 150154.
  • 12
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug teatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 19341943.
  • 13
    Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol 1991; 48: 796799.
  • 14
    Ishibashi A, Egashira N, Mishima K, Iwasaki K, Fujiwara M. Study on the central action of Yoku-kan-san. Yakugaku Zasshi 2006; 126: 8284 (in Japanese).
  • 15
    Kanno H, Iizuka S, Kawakami Z et al. Effect of yokukansan on extracellular glutamate in the ventral posterior medial thalamus of thiamine-deficient rats. J Pharmacol Sci 2008; 106 (Suppl. 1): 136 (Abstract).
  • 16
    Ikarashi Y. Ameliorative effects by Yokukansan on BPSD-like behaviors observed in various animal models. Rhonen Seishin Igaku Zasshi 2007; 18 (Suppl. II): 4649 (in Japanese).
  • 17
    Yabe T, Toriizuka K, Yamada H. Effects of kampo medicines on choline acetyltransferase activity in rat embryo septal cultures. J Tradit Med 1995; 12: 5460.
  • 18
    Ito T. Regulatory effects of yoku-kan-san-ka-chimpi-hange and saiko-ka-ryukotsu-borei-to on function of the central nervous system. Prog Med 1997; 17: 823830 (in Japanese).
  • 19
    Tanabe H, Ikeda M, Komori K. Behavioral symptomatology and care of patients with frontotemporal lobe degeneration-based on the aspects of the phylogenetic and ontogenetic processes. Dement Geriatr Cogn Disord 1999; 10: 5054.